Sophia Abene

First case this year without a documented occupational exposure to infected animals.

James Graham, CEO discussed the company's progress in developing a new antibiotic for sepsis and diabetic foot ulcers.

Britton Strickland, MD discusses innovations in microbiome research and their impact on antimicrobial resistance.

Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.

Akhila Kosaraju, MD, addresses overcoming key challenges in antibiotic development using AI, a nonprofit model, and supportive policies.

Insights from Catherine Bertrand Ferrandis, DVM, on the role of One Health and interdisciplinary collaboration.

The Phase 1/2 study of VAX-31 demonstrated that the vaccine was well tolerated and elicited strong opsonophagocytic activity immune responses across all 31 evaluated serotypes.

Results in about 5.5 to 6 hours, employing advanced technology to detect bacterial growth and minimum inhibitory concentration.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.

As the WHO seeks Emergency Use Listing for new diagnostics due to rising cases in the Democratic Republic of the Congo, 50,000 doses of this vaccine will be donated to Central Africa.

This week, MP Biomedicals launched rapid diagnostic tests for gastrointestinal pathogens, Invivyd's monoclonal antibody pemivibart shows an 84% reduction in symptomatic COVID-19 risk, Nestlé is acquiring global rights to the Vowst therapy for CDI, and more.

Approved for individuals aged 12 years and older, this vaccine features a monovalent component and replaces the previous Novavax formula.

The most recent National Healthcare Safety Network annual survey shows that 78% of US hospitals now have sepsis committees, an increase from 73% in 2022.

The FDA, CDC, and state health departments have been monitoring foodborne illnesses this August including Listeria, Salmonella, and Clostridium botulinum.

As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.

MP Biomedicals’ tests detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.

The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.

Two recent CDC Morbidity and Mortality Weekly Report (MMWR) studies show stable overall vaccination rates for 2023 but a decline in HPV vaccination rates for certain birth cohorts.

Nestlé aims to increase the global availability of Vowst, an FDA-approved therapy indicated for a healthcare-associated infection, while also seeking new opportunities for the product worldwide.

This virus is known for causing mild illness and the distinctive "slapped cheek" rash in children and has recently shown an unusual increase in activity.

This week, Pfizer-BioNTech's Phase 3 trial of a COVID-19 and influenza combination vaccine yielded mixed results, mpox as a global health emergency emphasizes need for coordinated international response, ongoing challenges with MRSA infections, and more

The study found that vancomycin is more effective than metronidazole in achieving event-free survival for C difficile infections across all infection severity levels.

The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.

The NIH’s RECOVER Initiative has developed new symptom indices for Long COVID in school-age children and adolescents to find 14 symptoms overlapping between the two groups.

This study provides evidence that using DAAs reduces liver fibrosis and improves clinical outcomes.

In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.

The study found that the vaccine, combined with presumptive antimalarial treatment, reduced Plasmodium falciparum parasitaemia and clinical malaria over two transmission seasons.

Mpox virus evades the innate immune system by interfering with antiviral pathways signaling and interferon responses, increasing replication, and complicating outbreak management, especially in non-endemic regions.

Recent study establishes that the generic glecaprevir/pibrentasvir is bioequivalent to the brand name version, offering the same therapeutic benefits.

NOWDiagnostics' represents a new option for early syphilis detection and aligns with ongoing efforts to improve STI screening.